OneMedNet expands real-world data network to over 121 million exams

MINNEAPOLIS - OneMedNet Corporation (NASDAQ:ONMD), currently trading at $0.68 after a remarkable 90% surge over the past week, has expanded its medical imaging-rich real-world data (RWD) repository to more than 121 million clinical exams through partnerships with over 1,400 hospital and healthcare provider sites, according to a company statement released Wednesday. According to InvestingPro analysis, the stock appears overvalued at current levels despite its recent momentum.

The AI-powered real-world data company has established partnerships with five major data marketplaces including Amazon Data Exchange, Protege AI, Bayer Data Marketplace, Datavant, and HealthVerity, expanding its market reach across multiple segments of the healthcare data ecosystem. However, InvestingPro data reveals concerning financials, with a negative gross profit margin of -82% and rapidly depleting cash reserves.

OneMedNet’s platform uses AI tools to search, de-identify, and curate datasets at scale. The company reports its network is growing organically by approximately 5% annually through daily patient care activities.

According to the company, its datasets meet FDA and international standards, enabling real-world evidence for regulatory submissions, post-market surveillance, and research. The company has implemented a subscription-based Data License Agreement structure aimed at driving annual recurring revenue.

The company provides data to train and validate AI models in medical imaging and diagnostics, and has expanded its AI anonymization technology beyond healthcare to industries including finance, telecom, and retail.

OneMedNet’s shareholder letter, issued by President and CEO Aaron Green, highlighted increased participation in industry trade shows and targeted campaigns, which the company says generated over 130 qualified leads, representing a threefold increase from previous years.

The statement indicates that OneMedNet’s customers include life sciences organizations using the data for clinical trials, regulatory submissions, and AI model development.

Based on a press release statement, the company’s platform supports near real-time data updates, with revenue being shared with partner hospitals and clinics. With current revenue at just $0.53 million and significant cash burn, investors should note that InvestingPro has identified 9 additional key investment factors for ONMD. Unlock comprehensive analysis and real-time alerts with an InvestingPro subscription.

In other recent news, OneMedNet Corporation has raised approximately $3.7 million through private placement transactions with accredited investors at $0.42 per share. The funds are intended for working capital and general corporate purposes, according to the company. In the second quarter of 2025, OneMedNet took significant steps to strengthen its balance sheet by reducing its total liabilities by around 60% compared to the figures from March 31. This included settling deferred underwriter fees, additional trade payables, and converting principal and interest into common stock, among other measures. These actions collectively settled or converted about $11 million of the company’s current liabilities. In a separate development, OneMedNet received a notification from The Nasdaq Stock Market LLC regarding non-compliance with the minimum bid price requirement. The company has 180 days, ending on October 7, 2025, to regain compliance by maintaining a minimum bid price of $1.00 for at least ten consecutive business days. OneMedNet is considering options, such as a reverse stock split, to address this issue and avoid potential delisting.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.